Base de dados : MEDLINE
Pesquisa : Hiperplasia [Palavras]
Referências encontradas : 72753 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7276 ir para página                         

  1 / 72753 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376615
[Au] Autor:Kamalov AA; Takhirzade AM
[Ad] Endereço:Department of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov MSU, Moscow, Russia.
[Ti] Título:[Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
[So] Source:Urologiia;(6):160-163, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews the results of various conservative treatments for concomitant benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Phosphodiesterase type 5 (PDE5) inhibitors remain the first-line therapy for this category of patients taking into account their positive effect on both ED and BPH. The preferred treatment scheme includes PDE-5 inhibitor co-administered with 1-adrenoblocker. However, other combination treatments are considered promising, for example, a PDE-5 inhibitor with a 5-reductase inhibitor or a three-component treatment regimen: 1-adrenoblocker + 5-reductase inhibitor + PDE-5 inhibitor. All these approaches to treating patients with BPH and ED have demonstrated high efficiency and safety. Nevertheless, a limited number of randomized clinical trials and short-term observations suggest the need for further studies investigating the long-term outcomes of different treatment options for such patients.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Disfunção Erétil
Inibidores da Fosfodiesterase 5/uso terapêutico
Hiperplasia Prostática
[Mh] Termos MeSH secundário: Disfunção Erétil/tratamento farmacológico
Disfunção Erétil/etiologia
Disfunção Erétil/patologia
Disfunção Erétil/fisiopatologia
Seres Humanos
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/patologia
Hiperplasia Prostática/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Phosphodiesterase 5 Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376601
[Au] Autor:Orlov IN; Popov SV; Martov AG; Gallyamov EA; Malevich SM; Sushina IV; Grin EA; Sanzharov AE; Novikov AB; Sergeev VP; Kochkin AD
[Ad] Endereço:St. Lukes Clinical Hospital, St. Petersburg, Russia.
[Ti] Título:[Comparative assessment of treatments for prostate adenoma greater than 100 cm3].
[So] Source:Urologiia;(6):82-86, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To compare holmium laser enucleation of the prostate (HoLEP) and endovideosurgical (EVS) adenomectomy in the treatment of prostate adenoma. MATERIALS AND METHODS: We compared treatment results of 180 patients with prostate adenomas greater than 100 cm3 who underwent EVS adenomectomy (n=90) and laser enucleation of the prostate (n=90). The analysis included the following parameters: duration of catheterization, length of postoperative hospital stay, I-PSS score, maximum urinary flow rate measured by uroflowmetry and complications according to Clavien-Dindo grading systems. RESULTS: There were no significant differences in patient age, preoperative prostate size, glandular tissue weight, and operative time. The duration of catheterization (p=0.0008) and length of postoperative hospital stay (p<0.0001) were significantly shorter in the HoLEP group. Both groups showed a statistically significant improvement in functional performance at three months post-surgery. Complications in the HoLEP and EVS adenomectomy group occurred in 18 (20%) and 23 (25.55%) patients, respectively (p>0.99). CONCLUSION: The two methods mentioned above are widely used in the treatment of prostate adenoma. However, holmium laser enucleation of the prostate shows similar short-term functional results and complication rates compared with EVS adenomectomy for prostate adenomas greater than 100 cm3. The patients of the HoLEP group had better results regarding the duration of catheterization and length of postoperative hospital stay. Therefore, laser enucleation is the preferred surgical modality for prostate adenomas greater than 100 cm3.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Tempo de Internação
Próstata/cirurgia
Hiperplasia Prostática/cirurgia
Cirurgia Vídeoassistida/métodos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Próstata/patologia
Hiperplasia Prostática/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  3 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376600
[Au] Autor:Biktimirov RG; Martov AG; Biktimirov TR; Kaputovskii AA
[Ad] Endereço:Federal Clinical Center for High Medical Technologies FMBA of Russia, Moscow Region, Khimki, Russia.
[Ti] Título:[The role of extraperitoneoscopic adenomectomy in the management of benign prostatic hyperplasia greater than 80 cm3].
[So] Source:Urologiia;(6):76-81, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:INTRODUCTION: The current standard of surgery for benign prostatic hyperplasia (BPH) greater than 80 cm3 includes open adenomectomy and holmium enucleation. Transurethral resection and laser vaporization are second line interventions, while the role of laparoscopic extraperitoneal adenomectomy is not fully understood. AIM: To evaluate the role of laparoscopic technique as a surgical modality for BPH greater than 80 cm3. MATERIALS AND METHODS: This study retrospectively evaluated the results of 79 patients (mean age 68 years) who underwent transcapsular extraperitoneoscopic adenomectomy from 2011 to 2016. RESULTS: The mean operative time was 206 (100-450) min; the prostate volume was 134 (80-300) cm3, blood loss was 256 (30-1200) ml. The I-PSS score after surgery decreased by an average of 18.3 points, the maximum urinary flow rate increased by 12 ml/s, the residual urine volume reduced from 147 to 28 ml. 35 (44%) patients underwent simultaneous operations (inguinal hernioplasty, cystolithotomy, etc.). There was one intraoperative complication, and 10 (12.6%) patients had postoperative complications. There were no conversions to open surgery. Incidental prostate cancer was detected in one patient. None of the patients required repeat surgery for infravesical obstruction. CONCLUSION: Extraperitoneoscopic adenomectomy is efficient, safe and reproducible surgical modality able to take the place of open surgery. There is a need for an evidence base to support the optimal choice between various minimally invasive techniques. Currently, laparoscopic procedure is more justified in patients with concomitant diseases, which can be simultaneously corrected.
[Mh] Termos MeSH primário: Laparoscopia/métodos
Hiperplasia Prostática/cirurgia
Procedimentos Cirúrgicos Urológicos Masculinos/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Hiperplasia Prostática/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  4 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376596
[Au] Autor:Krivoborodov GG; Efremov NS; Bolotov AD
[Ad] Endereço:Department of Urology and Andrology, Medical Faculty of N.I. Pirogov RNRMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Transabdominal and transrectal ultrasound assessment of intravesical prostatic protrusion].
[So] Source:Urologiia;(6):55-58, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:RELEVANCE: Benign prostatic hyperplasia (BPH) is one of the most common urological diseases among men. Despite the noticeable positive effects of pharmacotherapy on the quality of urination in BPH, the presence of an intravesical obstruction (IVO) leads to discontinuation of conservative treatment in favor of surgical interventions. One of the features of prostate enlargement is the degree of its intravesical growth (intravascular prostatic protrusion, IPP). According to some studies, IPP value of 10 mm or more is indicative of IVO in virtually all men. AIM: To compare transabdominal and transrectal ultrasound measurement of IPP in men with BPH. MATERIALS AND METHODS: The study comprised 108 men aged 69+/-10 years (43 to 93 years) with lower urinary tract symptoms and BPH. Patients underwent a standard urological examination. The shape of the prostate, prostate volume and the measurements of the IPP were assessed using transabdominal and transrectal ultrasound. RESULTS: The IPP measurements obtained using transabdominal and transrectal ultrasound were 9.8+/-5.7 mm (1.1 to 28 mm) and 9.3+/-5.3 mm (0.5 to 26 mm), respectively. The IPP measurements evaluated by transabdominal and transrectal ultrasound were found comparable regardless of the prostate volume. CONCLUSION: Similar results in assessing PPI by both ultrasound modalities allow them to be used equally effectively.
[Mh] Termos MeSH primário: Hiperplasia Prostática/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Ultrassonografia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  5 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29203758
[Au] Autor:Stefanski M; Brulinski K; Stefanska M
[Ad] Endereço:Oddzial Chirurgii Klatki Piersiowej, Centrum Pulmonologii I Torakochirurgii, Bystra, Polska.
[Ti] Título:[Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (dipnech) - an overview of the cases diagnosed at the department of thoracic surgery in the years 2010-2014].
[So] Source:Wiad Lek;70(5):1005-1012, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:INTRODUCTION: Pulmonary neuroendocrine cells (PNEC) are present in the normal lungs with the incidence of 1 in 2500 epithelial cells. They usually proliferate in the presence of reactive processes related to inflammation and fibrosis of the lung parenchyma. The division of pulmonary neuroendocrine cell hyperplasia proposed by Travis et al. additionally distinguished diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) or proliferation that occurs in people without reactive hyperplasia risk factors. The confirmation of the DIPNECH diagnosis requires staining of biopsy specimens using the immunohistochemical technique for neuroendocrine markers. AIM: The aim of this study is to overview the cases of 5 patients in whom the histopathological DIPNECH diagnosis was made in the process of invasive diagnostics performed at the Department of Thoracic Surgery. The aim of the study is to evaluate typical clinical, functional, radiological and histopathological features of this rare disease syndrome. MATERIAL AND METHODS: In the period from April 2010 to June 2014, five patients with lesions in the lungs were subjected to invasive diagnostics. Histopathological and immunohistochemical examinations of the collected specimens were used to make the DIPNECH diagnosis in these patients. The natural history of the disease was traced based on a 5-year follow-up in one of the patients. In addition, we analyzed the literature with regard to the described cases. CONCLUSIONS: Thanks to the early diagnosis of non-specific lesions in the lungs, typical carcinoid which develops on the basis of discussed DIPNECH, was found in the resected material in two out of five operated patients. The accurate diagnosis of DIPNECH allows for the implementation of appropriate treatment and channels further management of the patient into the right direction.
[Mh] Termos MeSH primário: Hiperplasia/diagnóstico por imagem
Hiperplasia/patologia
Pneumopatias/diagnóstico por imagem
Pneumopatias/patologia
Células Neuroendócrinas/patologia
[Mh] Termos MeSH secundário: Idoso
Proliferação Celular
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Testes de Função Respiratória
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  6 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181576
[Au] Autor:Araújo R; Santos JMO; Fernandes M; Dias F; Sousa H; Ribeiro J; Bastos MMSM; Oliveira PA; Carmo D; Casaca F; Silva S; Medeiros R; Gil da Costa RM
[Ad] Endereço:Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
[Ti] Título:Expression profile of microRNA-146a along HPV-induced multistep carcinogenesis: a study in HPV16 transgenic mice.
[So] Source:J Cancer Res Clin Oncol;144(2):241-248, 2018 Feb.
[Is] ISSN:1432-1335
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Persistent human papillomavirus (HPV) infection is associated with the development of certain types of cancer and the dysregulation of microRNAs has been implicated in HPV-associated carcinogenesis. This is the case of microRNA-146a (miR-146a), which is thought to regulate tumor-associated inflammation. We sought to investigate the expression levels of miR-146a during HPV16-mediated carcinogenesis using skin samples from K14-HPV16 transgenic mice which develop the consecutive phases of the carcinogenesis process. METHODS: Female transgenic (HPV ) and wild-type (HPV ) mice were sacrificed at 24-26 weeks-old or 28-30 weeks-old. Chest and ear skin samples from HPV and HPV mice were histologically classified and used for microRNA extraction and quantification by qPCR. RESULTS: Chest skin samples from 24 to 26 weeks-old HPV mice presented diffuse epidermal hyperplasia and only 22.5% showed multifocal dysplasia, while at 28-30 weeks-old all (100.0%) HPV animals showed epidermal dysplasia. All HPV ear skin samples showed carcinoma in situ (CIS). MiR-146a expression levels were higher in HPV compared to HPV mice (p = 0.006). There was also an increase in miR-146a expression in dysplastic skin lesions compared with hyperplasic lesions (p = 0.011). Samples showing CIS had a significant decrease in miR-146a expression when compared to samples showing epidermal hyperplasia (p = 0.018) and epidermal dysplasia (p = 0.009). CONCLUSIONS: These results suggest that HPV16 induces the overexpression of miR-146a in the initial stages of carcinogenesis (hyperplasia and dysplasia), whereas decreases its expression at later stages (CIS). Taken together, these data implicate and suggest different roles of miR-146a in HPV-mediated carcinogenesis.
[Mh] Termos MeSH primário: Carcinogênese/genética
Papillomavirus Humano 16/genética
MicroRNAs/biossíntese
[Mh] Termos MeSH secundário: Animais
Carcinogênese/metabolismo
Carcinogênese/patologia
Feminino
Hiperplasia/virologia
Camundongos
Camundongos Transgênicos
MicroRNAs/genética
Infecções por Papillomavirus/genética
Infecções por Papillomavirus/metabolismo
Infecções por Papillomavirus/virologia
Pele/patologia
Pele/virologia
Neoplasias Cutâneas/genética
Neoplasias Cutâneas/metabolismo
Neoplasias Cutâneas/patologia
Neoplasias Cutâneas/virologia
Transcriptoma
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MicroRNAs); 0 (Mirn146 microRNA, mouse)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-017-2549-5


  7 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157621
[Au] Autor:Lurain K; Yarchoan R; Uldrick TS
[Ad] Endereço:HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892-1868, USA.
[Ti] Título:Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):75-88, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a rare, polyclonal lymphoproliferative disorder characterized by flares of inflammatory symptoms, edema, cytopenias, lymphadenopathy, and splenomegaly. Diagnosis requires a lymph node biopsy. Pathogenesis is related to dysregulated inflammatory cytokines, including human and viral interleukin-6. Rituximab alone or in combination with chemotherapy, such as liposomal doxorubicin, has led to an overall survival of over 90% at 5 years. Experimental approaches to treatment include virus activated cytotoxic therapy with high-dose zidovudine and valganciclovir and targeting human interleukin-6 activity. Despite successful treatment of KSHV-MCD, patients remain at high risk for developing non-Hodgkin lymphomas.
[Mh] Termos MeSH primário: Doença de Castleman/tratamento farmacológico
Doxorrubicina/uso terapêutico
Ganciclovir/análogos & derivados
Herpesvirus Humano 8
Rituximab/uso terapêutico
Zidovudina/uso terapêutico
[Mh] Termos MeSH secundário: Biópsia
Doença de Castleman/diagnóstico
Doença de Castleman/metabolismo
Doença de Castleman/patologia
Ganciclovir/uso terapêutico
Seres Humanos
Interleucina-6/antagonistas & inibidores
Interleucina-6/metabolismo
Linfonodos/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (IL6 protein, human); 0 (Interleukin-6); 4B9XT59T7S (Zidovudine); 4F4X42SYQ6 (Rituximab); 80168379AG (Doxorubicin); GCU97FKN3R (valganciclovir); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  8 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157622
[Au] Autor:van Rhee F; Greenway A; Stone K
[Ad] Endereço:UAMS Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, #816, Little Rock, AR 72205, USA. Electronic address: vanrheefrits@uams.edu.
[Ti] Título:Treatment of Idiopathic Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):89-106, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Important progress has been made in the treatment of idiopathic multicentric Castleman disease (iMCD) with the introduction of interleukin-6 targeting monoclonal antibodies. This article describes the clinical results obtained with different treatment modalities and uses this evidence to provide treatment guidelines for the practicing clinician. Much is still to be learned about the pathophysiology of iMCD and further research is urgently needed to develop novel and curative treatment approaches for all patients.
[Mh] Termos MeSH primário: Antineoplásicos Imunológicos/uso terapêutico
Doença de Castleman/tratamento farmacológico
Interleucina-6/antagonistas & inibidores
[Mh] Termos MeSH secundário: Doença de Castleman/sangue
Doença de Castleman/patologia
Seres Humanos
Interleucina-6/sangue
Guias de Prática Clínica como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Immunological); 0 (IL6 protein, human); 0 (Interleukin-6)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  9 / 72753 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157620
[Au] Autor:Wong RSM
[Ad] Endereço:Department of Medicine and Therapeutics, Sir Y.K. Pao Cancer Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong. Electronic address: raymondwong@cuhk.edu.hk.
[Ti] Título:Unicentric Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):65-73, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder that manifests typically as proliferation of a single lymph node or region of lymph nodes. Histologically, hyaline vascular variant is found in a majority of UCDs. UCD commonly presents in younger patient populations. Patients with UCD may be asymptomatic or present with symptoms related to mass effects on surrounding structures. It is difficult to achieve a definitive diagnosis by imaging alone. Histologic examination of the lesion remains the gold standard for diagnosis. Complete surgical resection is the best primary treatment modality for UCD resulting in excellent long-term survival and low recurrence rates.
[Mh] Termos MeSH primário: Doença de Castleman/diagnóstico
Doença de Castleman/patologia
[Mh] Termos MeSH secundário: Fatores Etários
Doença de Castleman/mortalidade
Doença de Castleman/terapia
Intervalo Livre de Doença
Seres Humanos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  10 / 72753 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157619
[Au] Autor:Szalat R; Munshi NC
[Ad] Endereço:Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, M230 Boston, MA 02215, USA.
[Ti] Título:Diagnosis of Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):53-64, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Castleman disease (CD) is a rare and heterogenous group of disorders sharing in common an abnormal lymph node pathology. CD comprises distinct subtypes with different prognoses. Unicentric CD and multicentric CD are featured by specific systemic manifestations and may be associated with Kaposi sarcoma, non-Hodgkin and Hodgkin lymphoma, and POEMS syndrome. Multicentric CD is classically associated with systemic symptoms and poorer prognosis. In this article, the authors review how to diagnose the disease, keeping in context the clinical findings, biochemical changes and complications associated with CD.
[Mh] Termos MeSH primário: Doença de Castleman/diagnóstico
Doença de Castleman/patologia
Linfonodos/patologia
[Mh] Termos MeSH secundário: Doença de Hodgkin/diagnóstico
Doença de Hodgkin/patologia
Seres Humanos
Linfoma não Hodgkin/diagnóstico
Linfoma não Hodgkin/patologia
Síndrome POEMS/diagnóstico
Síndrome POEMS/patologia
Sarcoma de Kaposi/diagnóstico
Sarcoma de Kaposi/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE



página 1 de 7276 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde